Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Eli Lilly and Company
Pfizer
Astellas Pharma Inc
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Coherus Oncology, Inc.
Arcus Biosciences, Inc.
Pfizer
AstraZeneca
Baylor Research Institute
University of Miami
Novartis
City of Hope Medical Center
M.D. Anderson Cancer Center
GlaxoSmithKline
Pfizer
Mayo Clinic
Enliven Therapeutics
Massachusetts General Hospital
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Alabama at Birmingham
Toray Industries, Inc
The Methodist Hospital Research Institute
National Cancer Center, Japan
DEKA Biosciences
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hansoh BioMedical R&D Company
IGM Biosciences, Inc.
Memorial Sloan Kettering Cancer Center
Hansoh BioMedical R&D Company
Ohio State University Comprehensive Cancer Center
Ono Pharmaceutical Co. Ltd
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Ono Pharmaceutical Co. Ltd
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Taiho Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co. Ltd
National Cancer Institute (NCI)
Shanghai Zhongshan Hospital
OHSU Knight Cancer Institute
Sumitomo Pharma America, Inc.
University of Nebraska